Karyopharm files for bankruptcy to sell itself to Ayrmid

Overview

Updated 58 minutes ago

Karyopharm Therapeutics filed for Chapter 11 bankruptcy on November 2, 2026, and agreed to sell itself to Ayrmid Ltd., the Irish parent of cell therapy maker Gamida Cell. Ayrmid is the lead bidder, not the guaranteed buyer: the filing sets up a court-supervised auction where other offers can compete.

Karyopharm sells Xpovio, a blood cancer drug first approved in 2019, but has never turned a profit. It reported $115 million in net Xpovio sales against $196 million in losses in 2025, and carried a $1.8 billion accumulated deficit into the filing.

Why it matters

A drug that reached patients and still couldn't cover its costs shows how thin the margin is between a commercial biotech and insolvency.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$115M

Net Xpovio sales, 2025

Annual net product revenue from the company's only marketed drug.

$196M

Net loss, 2025

Annual loss reported in the company's 2025 annual report.

$1.8B

Accumulated deficit

Cumulative losses carried on the balance sheet at the time of filing.

$55M

Debtor-in-possession financing

Committed by existing secured lenders to fund operations during Chapter 11.

83%

Share price decline

Fall in Karyopharm stock on the bankruptcy announcement, to 11 cents a share.

$2.5M

Market value after filing

What the entire company was worth on the market after the announcement.

Voices

Curated perspectives — historical figures and your fellow readers.

People Involved

Joe Wiley

Chief executive of Ayrmid Ltd., the lead bidder

Leading the acquisition of Karyopharm through Chapter 11

Organizations Involved

Karyopharm Therapeutics Inc.

Commercial-stage pharmaceutical company

Debtor in possession; selling itself through Chapter 11

Massachusetts drugmaker whose only marketed product is the blood cancer drug Xpovio.

Ayrmid Ltd.

Pharmaceutical holding company

Lead bidder for Karyopharm's assets

Irish parent of cell therapy maker Gamida Cell, bidding to add Karyopharm's blood cancer drug to its portfolio.

Gamida Cell

Cell therapy developer

Subsidiary of Ayrmid; would absorb Karyopharm if the deal closes

Blood cancer cell therapy company whose parent is bidding for Karyopharm.

U.S. Bankruptcy Court for the Southern District of Texas

Federal court

Overseeing the Chapter 11 case and auction

Court handling Karyopharm's Chapter 11 case, docketed as No. 26-90827.

Timeline

2019 November 2026

5 events Latest: Yesterday

Tap a bar to jump to that date

November 2026
Chapter 11 filing and Ayrmid merger
Latest Legal

Karyopharm files in the Southern District of Texas with Ayrmid as lead bidder and $55 million in lender financing.
Yesterday
September 2026
Lenders grant forbearance
Legal

Karyopharm skips a $15.8 million principal payment and signs a forbearance deal through October 15.
September 10th, 2026
June 2026
Cash dwindles, interest skipped
Financial

Company holds $55 million in cash and misses interest payments on its convertible notes.
June 30th, 2026
2025
Losses outrun sales
Financial

Annual report shows $115 million in net Xpovio sales against $196 million in losses.
2025
2019
Xpovio reaches the market
Approval

U.S. regulators approve Karyopharm's drug for multiple myeloma; a lymphoma clearance follows.
2019

Scenarios

Ayrmid wins the auction and closes the merger

Likely Resolves by Q1 2027

Discussed by: Karyopharm and Ayrmid, in their joint announcement and court filings

No rival tops Ayrmid's stalking horse offer. The court approves the sale, the Chapter 11 plan is confirmed, and the transaction closes in the first quarter of 2027. Xpovio continues under new ownership, folded into a combined hematology business with Gamida Cell.

A rival bid tops Ayrmid at auction

Possible Resolves by Jan 31, 2027

Discussed by: Bankruptcy observers tracking the stalking horse process

The court-approved bidding procedures draw a competing offer above Ayrmid's. An auction sets the final price, and a different buyer, possibly a larger hematology company, takes Xpovio. Ayrmid's bid protections would entitle it to a breakup fee if it loses.

FDA clears Xpovio in myelofibrosis, lifting the sale price

Possible Resolves by Q2 2027

Discussed by: Karyopharm, which has a pending supplemental application for the combination

Regulators approve selinexor with ruxolitinib for myelofibrosis, adding a new patient population and revenue line. The clearance lands during the bankruptcy and raises what bidders will pay, or strengthens the reorganized company's case.

No qualified bid, assets sold off piecemeal

Unlikely Resolves by Q1 2027

Discussed by: Creditors and restructuring analysts weighing a liquidation path

The auction produces no qualified offer, or the lead bidder walks. The case converts to a Chapter 7 liquidation, Xpovio changes hands in fragments, and shareholders recover nothing. Ayrmid's chief executive has said the deal is not intended to end in liquidation.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

November 2014

Dendreon bankruptcy (2014)

Dendreon won approval in April 2010 for Provenge, the first therapeutic cancer vaccine, priced at $93,000 per course. Manufacturing constraints and slow reimbursement kept sales far below forecasts. The company filed for Chapter 11 in November 2014 and sold its assets to Sanofi.

Then

Provenge changed hands at a fraction of Dendreon's former valuation, and shareholders were wiped out.

Now

It became the standard cautionary tale for cancer therapies whose manufacturing or reimbursement costs outrun their sales.

Why this matters now

Karyopharm's Xpovio is a conventional pill, not a bespoke therapy, but the pattern matches: approval without enough revenue to cover the cost of getting there.

October 2013 - February 2017

Ariad Pharmaceuticals safety crisis (2013-2017)

Ariad's leukemia drug Iclusig was pulled from the U.S. market in October 2013 after reports of serious blood clots and heart problems. Regulators let it return months later with a narrower label and a boxed warning. Ariad rebuilt sales, and Takeda acquired the company in February 2017 for $5.2 billion.

Then

The withdrawal briefly threatened the company's survival and crushed its stock.

Now

A narrower label still supported a multibillion-dollar acquisition, showing a single niche cancer drug can carry a company if the economics work.

Why this matters now

It shows a label setback need not be fatal. Karyopharm's problem is different: demand and debt, not a safety recall, and its debt came due before a recovery.